{"article_id": "ZTS_q2_2020.txt", "article": ["in terms of numbers , our revenue grew 4 % operationally , with the u.s. segment up 6 % and international up 3 % .", "our companion animal products continue to drive our business performance , with 13 % operational growth , while livestock products declined 5 % .", "our adjusted net income increased 4 % operationally in the second quarter .", "our recently launched parasiticides , simparica trio , proheart 12 and revolution plus as well as our key dermatology portfolio of apoquel and cytopoint , provide a solid foundation that has continued to perform well this year .", "in terms of supply chain , zoetis has maintained a reliable inventory of critical medicines , vaccines and diagnostics to our customers and distributors in more than 100 markets around the world .", "we generated revenue of $ 1.5 billion , which was flat on a reported basis and 4 % growth operationally .", "adjusted net income of $ 427 million decreased 2 % on a reported basis and increased 4 % operationally .", "foreign exchange in the quarter had an unfavorable impact of 4 % on revenue .", "operational revenue growth of 4 % was driven by 2 % price and 2 % volume .", "volume growth of 2 % includes 3 % from new products , 3 % from key dermatology products , 1 % from acquisitions and a decline of 5 % in other in - line products .", "companion animal products led the way in terms of species growth , growing 13 % operationally , while livestock declined 5 % operationally .", "new products contributed 3 % to overall growth in the quarter , driven by simparica trio , proheart 12 , revolution plus and our alpha flux parasiticide for salmon in chile .", "we remain excited by the launch of simparica trio and are reaffirming the range of $ 100 million to $ 125 million for full year incremental revenue .", "global sales of our key dermatology portfolio were $ 224 million in the quarter , growing 24 % operationally and contributing 3 % to overall revenue growth .", "recent acquisitions contributed 1 % growth this quarter , which includes platinum performance and our reference lab expansion strategy .", "u.s. revenue grew 6 % , with companion animal products growing 19 % and livestock products declining by 18 % .", "u.s. key dermatology sales were $ 160 million for the quarter , growing 26 % .", "simparica trio performed well in the u.s. with sales of $ 36 million despite challenging market conditions in q2 .", "diagnostic sales increased 18 % in the quarter , largely driven by our reference lab acquisitions .", "u.s. livestock declined 18 % in the quarter , driven by lower sales across all species .", "our international segment had operational revenue growth of 3 % in the second quarter , with more balanced performance across our companion animal and livestock portfolios .", "companion animal operational revenue growth was 2 % and livestock operational growth was 4 % .", "swine grew double digits in the quarter , primarily driven by china , which grew 25 % , as key accounts continue to expand their herds and production shifts from smaller farms to larger - scale operations .", "adjusted gross margin of 71.1 % increased slightly on a reported basis compared to the prior year due to price , favorable manufacturing costs and product mix , which were partially offset by foreign exchange , recent acquisitions and higher inventory charges .", "the adjusted effective tax rate for the quarter was 22.3 % .", "adjusted net income for the quarter grew 4 % operationally , primarily driven by revenue growth , and adjusted diluted earnings per share grew 6 % operationally .", "we ended the second quarter with approximately $ 3.4 billion in cash and cash equivalents , including the proceeds from our $ 1.25 billion long - term debt issuance in may , of which $ 500 million is earmarked for repayment of our november 2020 maturity .", "we have access to a $ 1 billion revolving credit facility and a coinciding commercial paper program , both of which remain undrawn .", "with regard to returning excess cash to shareholders , we remain committed to our 2020 dividend , which represents a 22 % increase over 2019 .", "in q1 , we repurchased $ 250 million in zoetis shares before suspending the program in the second quarter in order to conserve cash .", "we have approximately $ 1.4 billion remaining under our multiyear share repurchase program .", "our current guidance includes favorable foreign exchange revenue of approximately $ 50 million and approximately $ 10 million at adjusted net income versus may guidance .", "for revenue , we are raising and narrowing our guidance range with projected revenue now between $ 6.3 billion and $ 6.475 billion and operational revenue growth of between 3 % and 6 % for the full year versus a negative 2 % to positive 3 % we had in our may guidance .", "adjusted net income is now expected to be in the range of between $ 1.685 billion and $ 1.765 billion , representing operational growth , a positive 1 % to positive 5 % compared to our prior guidance of negative 9 % to negative 2 % .", "adjusted diluted earnings per share is now expected to be in the range of $ 3.52 to $ 3.68 and reported diluted earnings per share to be in the range of $ 3.14 to $ 3.32 ."], "summary_gold": "sees fy 2020 earnings per share $ 3.14 to $ 3.32 .<q>sees fy 2020 revenue $ 6.3 billion to $ 6.475 billion .<q>q2 revenue $ 1.5 billion versus refinitiv ibes estimate of $ 1.36 billion .<q>sees fy 2020 adjusted earnings per share $ 3.52 to $ 3.68 .<q>looking ahead , expect overall revenue growth for remainder of year to be driven largely by companion animal products .", "summary_pred": "adjusted net income for the quarter grew 4 % operationally , primarily driven by revenue growth , and adjusted diluted earnings per share grew 6 % operationally .<q>adjusted gross margin of 71.1 % increased slightly on a reported basis compared to the prior year due to price , favorable manufacturing costs and product mix , which were partially offset by foreign exchange , recent acquisitions and higher inventory charges .<q>global sales of our key dermatology portfolio were $ 224 million in the quarter , growing 24 % operationally and contributing 3 % to overall revenue growth .<q>in terms of supply chain , zoetis has maintained a reliable inventory of critical medicines , vaccines and diagnostics to our customers and distributors in more than 100 markets around the world .<q>in q1 , we repurchased $ 250 million in zoetis shares before suspending the program in the second quarter in order to conserve cash .<q>for revenue , we are raising and narrowing our guidance range with projected revenue now between $ 6.3 billion and $ 6.475 billion and operational revenue growth of between 3 % and 6 % for the full year versus a negative 2 % to positive 3 % we had in our may guidance .<q>we remain excited by the launch of simparica trio and are reaffirming the range of $ 100 million to $ 125 million for full year incremental revenue .<q>we have approximately $ 1.4 billion remaining under our multiyear share repurchase program .<q>our companion animal products continue to drive our business performance , with 13 % operational growth , while livestock products declined 5 % .<q>with regard to returning excess cash to shareholders , we remain committed to our 2020 dividend , which represents a 22 % increase over 2019 .<q>recent acquisitions contributed 1 % growth this quarter , which includes platinum performance and our reference lab expansion strategy .<q>we have access to a $ 1 billion revolving credit facility and a coinciding commercial paper program , both of which remain undrawn .<q>volume growth of 2 % includes 3 % from new products , 3 % from key dermatology products , 1 % from acquisitions and a decline of 5 % in other in - line products .<q>simparica trio performed well in the u.s. with sales of $ 36 million despite challenging market conditions in q2 .", "len_article": 35, "len_summary_gold": 5, "len_summary_pred": 14, "len_sent_scores": 35}